Genome medicine in cancer: What's in a name?

Cancer Research

Volumn 75, Issue 10, 2015, Pages 1930-1935

  Schott, Anne F ^a   Perou, Charles M ^b   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; VEMURAFENIB;

ALK GENE; BREAST CANCER; CANCER GENETICS; CANCER HORMONE THERAPY; EGFR GENE; GENE MUTATION; GENOME ANALYSIS; HUMAN; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; OFF LABEL DRUG USE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEMANTICS; SQUAMOUS CELL LUNG CARCINOMA; STOMACH CANCER; GENETICS; HUMAN GENOME; NEOPLASMS;

GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84937965263     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0174     Document Type: Review

References (15)

1. The Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
2. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446-51.
3. Omenn G, Nass S, Micheel C, eds. Evolution of translational omics: lessons learned and the path forward. Washington, DC: National Academies Press; 2012.
4. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
5. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
6. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The evaluation of genomic applications inpractice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009;11:3-14.
7. Deverka PA, Dreyfus JC. Clinical integration of next generation sequencing: coverage and reimbursement challenges. J Law Med Ethics 2014;42 Suppl 1:22-41.
8. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, et al. Breaking a vicious cycle. Sci Transl Med 2013;5:196cm196.
9. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101: 1446-52.
10. Gleevec(imatinib mesylate) NDA 21-335 package insert. 2001 [cited 2014 Sep 8]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/21-335-Gleevec-prntlbl.pdf.
11. Center for Drug Evaluation and Research NDA Review 21-588/S011, S012, S013, S014, S017. 2006 [cited 2014 Sep 8]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/021588-s011-gleevec.pdf.
12. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014;41:297-9.
13. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, et al. National Cancer Institute's precision medicine initiatives for the new national clinical trials network. Am Soc Clin Oncol Educ Book 2014:71-6.
14. NCI-MPACT: molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors. 2014 [cited 2015 Jan 14]. Available from: http://clinicaltrials.gov/show/NCT01827384.
15. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol 2014;11:432-8.